The ultimate goal for researchers in the ESSENCE trial was to find the right balance of semaglutide to resolve the damage caused by fat buildup in the liver (steatohepatitis) while at the same time to reduce scarring (fibrosis)
Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH
The drug or matching placebo were given for 12 months and the primary endpoint, as shown below, was a motor score used by neurologists (Movement Disorder Scale-Unified Parkinsons Disease Rating Scale) MDS-UPDRS Part III)
"Tirzepatide effectively reduced drive to eat, as well as food-cue-driven and other-cue-driven eating behavior." Nature Medicine This effect is due to tirzepatides action on both GIP and GLP-1 receptors, which slows gastric emptying, signals fullness to the brain, and improves insulin sensitivity
Most definitely, when the right medication dose is achieved you will probably only be eating 30% of what you are currently eating without the medication